NCT05430516

Brief Summary

In the absence of a vaccine, the spread of SARS-CoV-2 can only be mitigated via non-pharmaceutical interventions that reduce the risks of forward transmission. Currently, European policymakers are implementing combinations of fierce pandemic control measures. However, there is substantial uncertainty on the transmission dynamics of SARS-CoV-2 and, consequently, the effect of each specific mitigation intervention as well as their joint impact on the pandemic evolution. Moreover, it is uncertain how and when the Public Health response should be modified once the pandemic starts to slow. There is an urgent need for data that can help to further unravel the key transmission characteristics of SARS-CoV-2 in the population. Household studies are, therefore, a useful approach to obtain insight into the main determinants of transmission and to derive estimates of transmission parameters. By fully characterizing the critical process of SARS-CoV-2 household transmission and how they vary by patient and household characteristics, infection dynamics in the population can be further elucidated. Responding to SARS-CoV-2 effectively from a community care perspective will also require understanding the perceptions, beliefs, and actions taken by patients and the public. A 'bottom-up' understating of such issues is critical to understand how best to design effective community strategies. Rapid European COVID-19 Emergency Research response (RECOVER) is a project involving ten international partners that have been selected for funding by the European Union under the Horizon 2020 research framework. RECOVER responds to call topic SC1-PHE-CORONAVIRUS-2020: Advancing knowledge for the clinical and public health response to the SARS-CoV-2 epidemic and builds on many years of investment by the European Commission in clinical research preparedness for epidemic response. RECOVER will therefore provide a range of data and analytical results to guide the Public Health response, including the here described household transmission study. Objective: Estimate key transmission parameters of SARS-CoV-2 in Europe from observing within household virus spread and seroconversion of household members and characterize the views and experiences of households regarding perceptions, practices regarding infection control, and impacts of imposed isolation measures.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
450

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2022

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 15, 2022

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

March 17, 2022

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2022

Completed
2 months until next milestone

First Posted

Study publicly available on registry

June 24, 2022

Completed
Last Updated

June 24, 2022

Status Verified

June 1, 2022

Enrollment Period

4 months

First QC Date

March 17, 2022

Last Update Submit

June 23, 2022

Conditions

Keywords

SARS-CoV-2OmicronChildrenHousehold studyTranmission

Outcome Measures

Primary Outcomes (1)

  • Estimate key transmission parameters of SARS-CoV-2 in Europe from observing within household virus spread and seroconversion of household members through study completion, an average of 4 weeks.

    Estimate key transmission parameters of SARS-CoV-2 in Europe from observing within household virus spread and seroconversion of household members. Including secondary attack rates and Transmission rate.

    Samples and data collected through study completion, an average of 4 weeks.

Secondary Outcomes (6)

  • Estimate the incubation period through study completion, an average of 4 weeks.

    Samples and data collected through study completion, an average of 4 weeks.

  • Estimate the generation time through study completion, an average of 4 weeks.

    Samples and data collected through study completion, an average of 4 weeks.

  • Estimate the susceptibility through study completion, an average of 4 weeks.

    Samples and data collected through study completion, an average of 4 weeks.

  • Estimate the infectiousness through study completion, an average of 4 weeks.

    Samples and data collected through study completion, an average of 4 weeks.

  • Estimate the transmission through study completion, an average of 4 weeks.

    Samples and data collected through study completion, an average of 4 weeks.

  • +1 more secondary outcomes

Study Arms (1)

Families

Patients with confirmed SARS-Cov-2 infection and their household members of all ages can be enrolled in the study, if at least one household member is a child age under 18.

Other: No intervention

Interventions

No intervention

Families

Eligibility Criteria

Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Communty within the region of Utrecht

You may qualify if:

  • All members of the household or their legal guardians consent to participation
  • All members of the household are willing to complete diaries and questionnaires for the duration of follow-up

You may not qualify if:

  • Patients or household members who are unable to consent, or do not wish to provide informed consent.
  • Children, pregnant women and patients lacking capacity will be included. Those lacking capacity to consent for themselves will be identified and consent will be sought from an appropriate consulted.
  • Households who do not have daily access to a smartphone or tablet with internet connection, will be excluded, as follow-up of households requires the use of an interactive diary App.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

UMC Utrecht

Utrecht, 3584CX, Netherlands

Location

Study Officials

  • Patricia Bruijning, MD PhD

    UMC Utrecht

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

March 17, 2022

First Posted

June 24, 2022

Study Start

January 15, 2022

Primary Completion

May 1, 2022

Study Completion

May 1, 2022

Last Updated

June 24, 2022

Record last verified: 2022-06

Locations